Chengda Pharmaceuticals Co (SZSE:301201) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301201 Chengda Pharmaceuticals Co Ltd SZSE:301201
78 GF Score
Price ¥29.75
GF Value ¥30.45
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Chengda Pharmaceuticals Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Chengda Pharmaceuticals Co is: Moderate Risk: Sensitive, better choose undervalued stock.

Chengda Pharmaceuticals Co  (SZSE:301201) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Chengda Pharmaceuticals Co Risk Assessment Related Terms

SZSE:301201 vs ZTS: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Chengda Pharmaceuticals Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chengda Pharmaceuticals Co Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chengda Pharmaceuticals Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Chengda Pharmaceuticals Co's Risk Assessment falls into.


SZSE:301201
78GF Score
Chengda Pharmaceuticals Co Ltd SZSE:301201
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Chengda Pharmaceuticals Co (SZSE:301201) Overvalued in 2026?

Based on GuruFocus' analysis, Chengda Pharmaceuticals Co stock appears to be undervalued. The current stock price of ¥29.75 is trading 2.3% below its estimated GF Value™ of ¥30.45. GuruFocus considers Chengda Pharmaceuticals Co to be Fairly Valued.

Key valuation signals for SZSE:301201:

  • Risk Assessment:
  • GF Value™: ¥30.45 vs. price of ¥29.75 (2.3% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the SZSE:301201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengda Pharmaceuticals Co Business Description

Address 36 Huanghe Road, Huimin Street, Jiashan County, Zhejiang Province, Jiaxing, CHN, 314100
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
78GF Score

Get the complete analysis for SZSE:301201

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥29.75
Price
¥30.45
GF Value